Phase 1 Ovarian Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You must be in generally good physical health and able to carry out daily activities with little to no limitation (this is measured by a standard health scale called ECOG, scored 0 or 1 — confirm with trial site if unsure which score applies to you)
- You must have at least one area of cancer in your body that doctors can safely take a small tissue sample (biopsy) from, separate from the main area being studied in the trial
- You must have a type of cancer (carcinoma) that cannot be removed by surgery or has spread to other parts of the body
Who may not be able to join:
- You cannot join if your cancer has spread to the membranes surrounding the brain or spinal cord
- You cannot join if you currently have another active cancer that requires treatment, or if you have had a separate cancer that was active at any point in the last 2 years
- You cannot join if you have had radiation therapy within the 2 weeks before starting this trial
- There are additional eligibility requirements set by the trial team that are not listed here (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Bristol-Myers Squibb, Bristol-Myers Squibb
Phone: 855-907-3286
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of participants with adverse events (AEs); Number of participants with serious adverse events (SAEs); Number of participants with AEs meeting protocol defined dose-limiting toxicity (DLT) criteria; Number of participants with AEs leading to discontinuation; Number of participants with AEs leading to death
Can't join this trial?
Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.